| Literature DB >> 34308062 |
Aishwarya Vetrivel1, Santhi Natchimuthu1, Vidyalakshmi Subramanian2, Rajeswari Murugesan1.
Abstract
<span class="Species">Pseudomonas aeruginosa, an opportunistic <span class="Species">human pathogen, causes fatal effects in patients with cystic fibrosis and immunocompromised individuals and leads to around 1000 deaths annually. The quorum sensing mechanism of P. aeruginosa plays a major role in promoting biofilm formation and expression of virulent genes. Hence, quorum sensing inhibition is a promising novel approach to treat these bacterial infections as these organisms show a wide range of antibiotic resistance. Among the interconnected quorum sensing network of P. aeruginosa, targeting the las system is of increased interest as its principal receptor protein LasR is the earliest activated gene. It is also shown to be involved in the regulation of other virulence-associated genes. In this study, we have applied high-throughput virtual screening, an in silico computational method to identify a new class of LasR inhibitors that could serve as potent antagonists to treat P. aeruginosa-associated infections. Three-tire structure-based virtual screening was performed on the Schrödinger small molecule database, which resulted in 12 top hit compounds with docking scores lesser than -11.0 kcal/mol. Three of these best-scored compounds CACPD2011a-0001928786 (C1), CACPD2011a-0001927437 (C2), and CACPD2011a-0000896051 (C3) were further analyzed. The binding free energies of these compounds in complex with the target protein LasR (3IX4) were evaluated, and the pharmacokinetic properties were determined. The stability of the docked complexes was assessed by running a molecular dynamics simulation for 100 ns. Molecular dynamics simulation analysis revealed that all three compounds were found to be in stable contact with the protein over the entire simulation period. The antagonistic effect of these compounds was validated using the LasR reporter gene assay in the presence of acyl homoserine lactone. Significant reduction in the β-galactosidase enzyme activity was achieved at 100 nM concentration for all three compounds pursued. Hence, the present study provides strong evidence that these three compounds could serve as quorum sensing inhibitors of P. aeruginosa LasR protein and can be a probable candidate to treat Pseudomonas-associated infections.Entities:
Year: 2021 PMID: 34308062 PMCID: PMC8296597 DOI: 10.1021/acsomega.1c02191
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Docking Scores and Hydrogen Bond Interactions of Hit Compounds
| compounds | XP docking score (kcal/mol) | no. of H-bonds | H-bond interaction residues |
|---|---|---|---|
| native ligand (autoinducer -OdDHL) | –7.5 | 4 | Tyr56, Asp73, Ser129, Trp60 |
| TP-1 (triphenyl mimic of autoinducer) | –12.8 | 4 | Tyr56, Asp73, Ser129, Trp60 |
| CACPD2011a-0001928786 | –13.0 | 3 | Tyr56, Ser129, Asp73 |
| CACPD2011a-0001927437 | –12.2 | 3 | Tyr56, Ser129, Asp73 |
| CACPD2011a-0000896051 | –11.7 | 0 | |
| CACPD2011a-0001779781 | –11.7 | 2 | Tyr56, Ser129 |
| CACPD2011a-0001734913 | –11.6 | 0 | |
| CACPD2011a-0002367758 | –11.4 | 3 | Tyr56, Ser129, Trp60 |
| CACPD2011a-0002145356 | –11.3 | 1 | Tyr56 |
| CACPD2011a-0001893654 | –11.2 | 0 | |
| CACPD2011a-0002017222 | –11.1 | 2 | Tyr56, Ser129 |
| CACPD2011a-0002215130 | –11.1 | 3 | Tyr56, Asp73, Thr115 |
| CACPD2011a-0002142621 | –11.0 | 1 | Ser129 |
| CACPD2011a-0000661063 | –11.0 | 3 | Tyr56, Asp73, Leu110 |
Figure 1Two-dimensional (2D) structures of the top three selected compounds: (A) CACPD2011a-0001928786, (B) CACPD2011a-0001927437, and (C) CACPD2011a-0000896051.
Figure 2Ligand interaction diagram for the top three compounds docked with LasR (PDB:3IX4): (A) CACPD2011a-0001928786 (C1), (B) CACPD2011a-0001927437 (C2), and (C) CACPD2011a-0000896051 (C3).
Figure 3Ligand interactions of the (A) native ligand with LasR and (B) TP-1 (triphenyl mimic of the autoinducer) with LasR.
Prime MM-GBSA Binding Energy Calculation of the Docked Complexesa
| compounds | Δ | Δ | Δ | Δ | Δ | SELig |
|---|---|---|---|---|---|---|
| native ligand | –93.7 | –16.7 | –44.2 | –49.3 | 16.0 | 13.5 |
| TP-1 | –147.4 | –20.8 | –63.2 | –78.0 | 21.7 | 3.3 |
| C1 | –103.6 | –59.2 | –49.9 | –61.0 | 65.4 | 14.9 |
| C2 | –112.2 | –19.9 | –54.3 | –61.7 | 28.2 | 16.3 |
| C3 | –92.2 | –3.0 | –68.6 | –65.7 | 35.6 | 37.3 |
ΔGBind, MM-GBSA free binding energy; ΔGCoul, Coulomb energy of the complex; ΔGLipo, lipophilic energy of the complex; ΔGvdW, van der Waals energy of the complex; ΔGSolvGB, solvation energy of the complex; SELig, strain energy of the ligands.
ADMET and Drug-Likeness Profiles of Selected Compounds
| ADMET properties | C1 | C2 | C3 | optimal range (in 95% drugs) |
|---|---|---|---|---|
| molecular weight | 433.481 | 442.51 | 477.623 | 130.0–725.0 |
| no. of hydrogen bond donors | 3 | 0 | 1 | 0–6.0 |
| no. of hydrogen bond acceptors | 3.5 | 6.0 | 6.75 | 2.0–20.0 |
| predicted
aqueous solubility (QP log | –6.3 | –7.2 | –7.7 | –6.5–0.5 |
| predicted polarizability in cubic angstroms (QPPolrz) | 46.4 | 49.8 | 53.4 | 13.0–70.0 |
| predicted
hexane/gas partition coefficient (QP log | 14.4 | 13.9 | 15.1 | 4.0–18.0 |
| predicted octanol/gas partition coefficient
(QP log | 21.9 | 20.1 | 23.2 | 8.0–35.0 |
| predicted
water/gas partition coefficient (QP log | 12.0 | 9.9 | 10.9 | 4.0–45.0 |
| predicted octanol/water partition coefficient
(QP log | 5.2 | 5.4 | 6.0 | –2.0–6.5 |
| conformation-independent
predicted aqueous solubility (CIQP log | –6.9 | –6.9 | –7.4 | –6.5–0.5 |
| predicted IC50 value for blockage of
HERG K+ channels (QP log | –5.2 | –7.0 | –6.3 | concern = <−5 |
| predicted apparent Caco-2 cell permeability in nm/s (QPPCaco) | 1551.8 | 2414.1 | 3749.9 | <25 = poor; >500 = great |
| no. of primary metabolites (#metab) | 4 | 3 | 6 | 1.0–8.0 |
| predicted brain/blood partition coefficient (QP log BB) | –0.5 | –0.2 | –0.1 | –3.0–1.2 |
| predicted apparent MDCK cell permeability in nm/s (QPPMDCK) | 1566.7 | 2610.7 | 3581.6 | <25 = poor; >500 = great |
| predicted skin permeability (QP log | –0.8 | –1.0 | –0.9 | –8.0 to −1.0 |
| prediction of binding to human serum albumin (QP log | 0.7 | 0.8 | 1.1 | –1.5–1.5 |
| predicted human oral absorption (pHOA) | 100 | 100 | 100 | <25% is poor |
| predicted central nervous system activity (CNS) | –1 | 0 | 0 | –2 to +2 |
| number of violations of the 95% range (#stars) | 0 | 1 | 1 | |
| number of violations of
Lipinski’s rule of five ( | 1 | 1 | 1 | maximum is 4 |
| number of violations of Jorgensen’s
rule of three ( | 1 | 1 | 1 | maximum is 3 |
Figure 4Protein–ligand RMSD (Å) observed during the course of a 100 ns simulation study for (A) C1, (B) C2, and (C) C3 in complex with LasR.
Figure 5Protein–ligand interaction histogram plots for LasR and (A) C1, (B) C2, and (C) C3.
Figure 6Ligand torsion profiles of (A) C1, (B) C2, and (C) C3 during the simulation process.
Figure 7Variations in the ligand properties observed during the course of 100 ns simulation: (A) C1, (B) C2, and (C) C3.
Figure 8Inhibitory effect of compounds on β-galactosidase enzyme production assayed using the in vitro LasR reporter gene assay. The assay was performed in triplicates, and values are given as the mean ± standard deviation (SD). *p < 0.05 vs control, **p < 0.01 vs control, ***p < 0.001 vs control.